Related Experiment Video
Updated: Jun 24, 2025
09:36
Recombinant α- β- and γ-Synucleins Stimulate Protein Phosphatase 2A Catalytic Subunit Activity in Cell Free Assays
Published on: August 13, 2017
6.7K
A Potent Sybody Selectively Inhibits α-Synuclein Amyloid Formation by Binding to the P1 Region
Dimitra Gialama1, Devkee M Vadukul1, Rebecca J Thrush1,2
1Department of Chemistry, Molecular Sciences Research Hub, Imperial College London, London W12 0BZ, U.K.
Journal of Medicinal Chemistry
|June 6, 2024
Summary
Researchers developed a novel antibody fragment, αSP1, that specifically inhibits amyloid formation of alpha-synuclein, a key protein implicated in Parkinson's disease and related disorders.
Area of Science:
- Neuroscience
- Biochemistry
- Immunology
Background:
- Antibodies are being explored to inhibit amyloid formation in neurodegenerative diseases.
- Discovering specific antibodies for amyloid inhibition remains a significant challenge.
- Alpha-synuclein amyloid formation is central to Parkinson's disease and multiple-system atrophy.
Purpose of the Study:
- To screen for and identify synthetic single-domain antibodies (sybodies) targeting the P1 region of alpha-synuclein.
- To assess the ability of identified sybodies to inhibit alpha-synuclein amyloid formation.
- To characterize the specificity and mechanism of action of effective sybodies.
Main Methods:
- Ribosome display was employed to screen for sybodies targeting the P1 region (residues 36-42) of alpha-synuclein.
- Binding assays (e.g., Fluorescence Resonance Energy Transfer) were used to confirm direct interaction with P1 peptides.
- Amyloid formation inhibition assays and seeding experiments were conducted to evaluate functional efficacy.
Main Results:
- A specific sybody, designated αSP1, was discovered that effectively inhibits alpha-synuclein amyloid formation.
- αSP1 demonstrated efficacy at substoichiometric concentrations and maintained specificity in complex mixtures.
- Experiments confirmed the P1 region's critical role in both primary and secondary nucleation steps of alpha-synuclein assembly.
Conclusions:
- The synthetic single-domain antibody αSP1 represents a promising therapeutic candidate for inhibiting alpha-synuclein aggregation.
- Targeting the P1 region of alpha-synuclein is a viable strategy for developing specific inhibitors of amyloid formation.
- This study highlights the potential of sybodies in addressing challenges in neurodegenerative disease research.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
01:37Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
00:46Feedback Inhibition
53.8K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
53.8K